These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6866592)

  • 1. Methylphenidate hydrochloride given with or before breakfast: II. Effects on plasma concentration of methylphenidate and ritalinic acid.
    Chan YP; Swanson JM; Soldin SS; Thiessen JJ; Macleod SM; Logan W
    Pediatrics; 1983 Jul; 72(1):56-9. PubMed ID: 6866592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylphenidate hydrochloride given with or before breakfast: I. Behavioral, cognitive, and electrophysiologic effects.
    Swanson JM; Sandman CA; Deutsch C; Baren M
    Pediatrics; 1983 Jul; 72(1):49-55. PubMed ID: 6866591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability of modified-release methylphenidate: influence of high-fat breakfast when administered intact and when capsule content sprinkled on applesauce.
    Lee L; Kepple J; Wang Y; Freestone S; Bakhtiar R; Wang Y; Hossain M
    Biopharm Drug Dispos; 2003 Sep; 24(6):233-43. PubMed ID: 12973820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single-dose, two-way crossover, bioequivalence study of dexmethylphenidate HCl with and without food in healthy subjects.
    Teo SK; Scheffler MR; Wu A; Stirling DI; Thomas SD; Stypinski D; Khetani VD
    J Clin Pharmacol; 2004 Feb; 44(2):173-8. PubMed ID: 14747426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
    Research Units on Pediatric Psychopharmacology Autism Network
    Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children.
    Swanson J; Gupta S; Guinta D; Flynn D; Agler D; Lerner M; Williams L; Shoulson I; Wigal S
    Clin Pharmacol Ther; 1999 Sep; 66(3):295-305. PubMed ID: 10511066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: a pilot double-blind randomized trial.
    Mohammadi MR; Kashani L; Akhondzadeh S; Izadian ES; Ohadinia S
    J Clin Pharm Ther; 2004 Apr; 29(2):139-44. PubMed ID: 15068402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute impact of immediate release methylphenidate administered three times a day on sleep in children with attention-deficit/hyperactivity disorder.
    Corkum P; Panton R; Ironside S; Macpherson M; Williams T
    J Pediatr Psychol; 2008 May; 33(4):368-79. PubMed ID: 18056144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereoselective disposition of methylphenidate in children with attention-deficit disorder.
    Srinivas NR; Quinn D; Hubbard JW; Midha KK
    J Pharmacol Exp Ther; 1987 Apr; 241(1):300-6. PubMed ID: 3572792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose pharmacokinetics of multilayer-release methylphenidate and immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
    Quinn D; Bode T; Reiz JL; Donnelly GA; Darke AC
    J Clin Pharmacol; 2007 Jun; 47(6):760-6. PubMed ID: 17395894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neuropsychological effects of chronic methylphenidate on drug-naive boys with attention-deficit/hyperactivity disorder.
    Coghill DR; Rhodes SM; Matthews K
    Biol Psychiatry; 2007 Nov; 62(9):954-62. PubMed ID: 17543895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylphenidate dosing: twice daily versus three times daily.
    Stein MA; Blondis TA; Schnitzler ER; O'Brien T; Fishkin J; Blackwell B; Szumowski E; Roizen NJ
    Pediatrics; 1996 Oct; 98(4 Pt 1):748-56. PubMed ID: 8885956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.
    Marcus SC; Wan GJ; Kemner JE; Olfson M
    Arch Pediatr Adolesc Med; 2005 Jun; 159(6):572-8. PubMed ID: 15939858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE; McBurnett K; Bukstein O; McGough J; Greenhill L; Lerner M; Stein MA; Conners CK; Duby J; Newcorn J; Bailey CE; Kratochvil CJ; Coury D; Casat C; Denisco MJ; Halstead P; Bloom L; Zimmerman BA; Gu J; Cooper KM; Lynch JM
    Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. School observations of children with attention-deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment.
    Gadow KD; Nolan E; Sprafkin J; Sverd J
    J Dev Behav Pediatr; 1995 Jun; 16(3):167-76. PubMed ID: 7560119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Medori R; Ramos-Quiroga JA; Casas M; Kooij JJ; Niemelä A; Trott GE; Lee E; Buitelaar JK
    Biol Psychiatry; 2008 May; 63(10):981-9. PubMed ID: 18206857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of sustained-release and standard methylphenidate in the treatment of minimal brain dysfunction.
    Whitehouse D; Shah U; Palmer FB
    J Clin Psychiatry; 1980 Aug; 41(8):282-5. PubMed ID: 7400107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.